RAS-protein activation but not mutation status is an outcome predictor and unifying therapeutic target for high-risk acute lymphoblastic leukemia

• Main Authors: Koschut, David, Ray, Debleena, Li, Zhenhua, Giarin, Emanuela, Groet, Jurgen, Alic, Ivan, Kham, Shirley Kow-Yin, Chng, Wee Joo, Ariffin, Hany Mohd, Weinstock, David M., Yeoh, Allen Eng-Juh, Basso, Giuseppe, Nizetic, Dean
• Format: Article
• Published: Springer Nature 2021
• Subjects: QD Chemistry; R Medicine; RC Internal medicine; RC0254 Neoplasms. Tumors. Oncology (including Cancer)
• Online Access: http://eprints.um.edu.my/34530/

Leukemias are routinely sub-typed for risk/outcome prediction and therapy choice using acquired mutations and chromosomal rearrangements. Down syndrome acute lymphoblastic leukemia (DS-ALL) is characterized by high frequency of CRLF2-rearrangements, JAK2-mutations, or RAS-pathway mutations. Intrigui...